Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Business News, In Brief

Executive Summary

Companies discuss their plans to move pipelines forward as the third quarter wraps up and they prepare for new launches and new indications in the coming year.

You may also be interested in...



Bapineuzumab Failure Raises More Doubts About Beta Amyloid Approach In Alzheimer’s

As many observers expected, top-line results from a Phase III study show bapineuzumab doesn’t work in carriers of the ApoE4 gene, who are at highest risk for Alzheimer’s disease. An interim analysis of another Phase III study in carriers will now be “expedited,” and other studies of non-carriers will keep going, Pfizer says.

Regeneron/Sanofi’s Long-Term Alliances Begin Bearing Fruit

Regeneron’s five-year-old antibody partnership with Sanofi may be expensive, but it is starting to produce some interesting compounds in mid-to-late-stage clinical trials, with positive data to show.

Regeneron Plays It Safe With Eylea, Aims To Undercut Lucentis

Regeneron has designed the launch strategy of its bimonthly wet AMD injection Eylea to head off any reimbursement issues.

Topics

Related Companies

UsernamePublicRestriction

Register

PS054843

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel